326 related articles for article (PubMed ID: 26346638)
1. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
[TBL] [Abstract][Full Text] [Related]
2. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
4. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
Kornstein SG; Bliss C; Kando J; Madhoo M
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
Gasior M; Hudson J; Quintero J; Ferreira-Cornwell MC; Radewonuk J; McElroy SL
J Clin Psychopharmacol; 2017 Jun; 37(3):315-322. PubMed ID: 28383364
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
[TBL] [Abstract][Full Text] [Related]
9. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
10. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.
McElroy SL; Hudson JI; Mitchell JE; Wilfley D; Ferreira-Cornwell MC; Gao J; Wang J; Whitaker T; Jonas J; Gasior M
JAMA Psychiatry; 2015 Mar; 72(3):235-46. PubMed ID: 25587645
[TBL] [Abstract][Full Text] [Related]
12. Lisdexamfetamine: A Review in Binge Eating Disorder.
Heo YA; Duggan ST
CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
Childress AC; Lloyd E; Jacobsen L; Gunawardhana L; Johnson SA; Findling RL
J Am Acad Child Adolesc Psychiatry; 2022 Dec; 61(12):1423-1434. PubMed ID: 35577034
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.
Richards C; Iosifescu DV; Mago R; Sarkis E; Reynolds J; Geibel B; Dauphin M
J Psychopharmacol; 2017 Sep; 31(9):1190-1203. PubMed ID: 28857719
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
Ward K; Citrome L
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
McElroy SL; Coloma PM; Berger B; Guerdjikova AI; Joyce JM; Liebowitz MR; Pain S; Rabasa C
Int J Eat Disord; 2023 Nov; 56(11):2120-2130. PubMed ID: 37584285
[TBL] [Abstract][Full Text] [Related]
20. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
